Literature DB >> 24635486

C-reactive protein in Crohn's disease: how informative is it?

Fernando Magro1, Paula Sousa, Paula Ministro.   

Abstract

C-reactive protein (CRP) is an important acute-phase marker, produced mainly in the liver. Its production by mesenteric adipocytes has been recently stressed in Crohn's disease (CD). There are many factors affecting CRP levels, both environmental and genetics. The short-life of this biomarker makes it of pertinent use in the assessment of inflammation. There are inconsistent results concerning the association of clinical activity indices, mucosal healing, histological activity and CRP. This review summarizes the role of CRP in CD, namely its importance in the differential diagnosis of CD; its relationship with clinical activity indices, other markers of inflammation and endoscopic and radiological cross sectional imaging; prediction of response to anti-TNF treatment and prediction of outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24635486     DOI: 10.1586/17474124.2014.893821

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  9 in total

1.  Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.

Authors:  Michał Łodyga; Piotr Eder; Magdalena Gawron-Kiszka; Agnieszka Dobrowolska; Maciej Gonciarz; Marek Hartleb; Maria Kłopocka; Ewa Małecka-Wojciesko; Piotr Radwan; Jarosław Reguła; Edyta Zagórowicz; Grażyna Rydzewska
Journal:  Prz Gastroenterol       Date:  2021-11-19

2.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

3.  Validation and Optimization of an Ex Vivo Assay of Intestinal Mucosal Biopsies in Crohn's Disease: Reflects Inflammation and Drug Effects.

Authors:  Kasper Vadstrup; Elisabeth Douglas Galsgaard; Jens Gerwien; Marianne Kajbæk Vester-Andersen; Julie Steen Pedersen; Julie Rasmussen; Søren Neermark; Marianne Kiszka-Kanowitz; Teis Jensen; Flemming Bendtsen
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

4.  Can Dynamic Contrast-Enhanced MRI (DCE-MRI) and Diffusion-Weighted MRI (DW-MRI) Evaluate Inflammation Disease: A Preliminary Study of Crohn's Disease.

Authors:  Jianguo Zhu; Faming Zhang; Yun Luan; Peng Cao; Fei Liu; Wenwen He; Dehang Wang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

5.  Preoperatively elevated serum inflammatory markers increase the risk of periprosthetic joint infection following total knee arthroplasty in patients with osteoarthritis.

Authors:  Chi Xu; Heng Guo; Pengfei Qu; Jun Fu; Feng-Chih Kuo; Ji-Ying Chen
Journal:  Ther Clin Risk Manag       Date:  2018-09-17       Impact factor: 2.423

6.  Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.

Authors:  Fernando Magro; Susana Lopes; Marco Silva; Rosa Coelho; Francisco Portela; Diogo Branquinho; Luís Correia; Samuel Fernandes; Marília Cravo; Paulo Caldeira; Helena Tavares de Sousa; Marta Patita; Paula Lago; Jaime Ramos; Joana Afonso; Isabel Redondo; Patrícia Machado; George Philip; Joanne Lopes; Fátima Carneiro
Journal:  Therap Adv Gastroenterol       Date:  2019-08-30       Impact factor: 4.409

7.  Postoperative Ratio of C-Reactive Protein to Albumin as a Predictive Marker in Patients with Crohn's Disease Undergoing Bowel Resection.

Authors:  Hangfen Zhao; Huaying Liu; Weilin Qi; Wei Liu; Lingna Ye; Qian Cao; Xiaolong Ge; Wei Zhou; Xianfa Wang
Journal:  Gastroenterol Res Pract       Date:  2021-02-26       Impact factor: 2.260

8.  C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study.

Authors:  Fu-Sheng Zhou; Nan Gao; Xu Sun; Xiao-Yun Jiang; Jia-Jie Chen; Qi-Qi Mao; Liang Zhong
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

9.  Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

Authors:  N Vande Casteele; B G Feagan; S Vermeire; M Yassine; J Coarse; G Kosutic; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2017-11-21       Impact factor: 8.171

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.